Skip to content
Search

Latest Stories

Avril Chester to join RPS as Chief Technology Officer from June

The Royal Pharmaceutical Society (RPS) has appointed Avril Chester as its new Chief Technology Officer.

Avril joins the RPS in June and will be accountable for the development and implementation of the RPS technology and digital strategy. Last year RPS launched a new platform for the Pharmaceutical Journal and plans to develop more digital products and services for our members and customers.


In her new role, Avril will have responsibility for executive leadership of all the technology functions, including technical architecture, software development, operations and product delivery. Avril will report directly to the Chief Executive, Paul Bennett, and joins the Society’s Executive team in June.

Avril is currently Chief Technology Officer at the Royal Institute of British Architects. Alongside that, she is an award-winning technology entrepreneur, author, podcast host and founder of a cancer charity. She was also finalist for CTO of the Year at the Women in IT awards 2022.

Paul Bennett, CEO said: "I am delighted that Avril will be joining our Executive team and leading our technology function and our digital strategy. We have a strong technology team within RPS and Avril's appointment strengthens that further as she brings great energy, drive, experience and enthusiasm with her and my colleagues and I very much look forward to working closely with her as we further develop our technological capability"

Commenting on her appointment Avril said: “It is a real honour to support our incredible pharmacists and pharmaceutical scientists and I am over the moon to have this opportunity to join the Royal Pharmaceutical Society. Technology has and continues to impact our lives, especially in healthcare and medicine. The RPS already embraces the technology evolution and I look forward to continuing this great work and push even more digital boundaries to champion and support the profession”.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less